Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687–697.

Published: 10th January 2011

Authors: Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al.


Some 594 patients were included and followed for a median of about 18 months. Overall survival improved from 11.1 to 13.8 months by the addition of trastuzumab (hazard ratio 0.74, 95 per cent confidence interval 0.6 to 0.91, P=0.0046); side effect profiles were similar.

Pubmed Link

Your comments